What is Tasigna, and what patents cover it?
Tasigna is the brand name of nilotinib, a cancer medicine used for certain cases of Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML). Patent coverage for Tasigna depends on the specific jurisdiction (country) and the type of exclusivity being considered (active drug substance patents, formulation/use patents, and any periods of regulatory exclusivity).
DrugPatentWatch tracks published patent documents and patent status for specific drugs and can help identify which patents are listed for Tasigna in a given market: https://www.drugpatentwatch.com/
When does the Tasigna patent expire (or exclusivity end)?
The “when” depends on the country and on which patent (or regulatory exclusivity) you mean. In many markets, multiple patents can extend exclusivity beyond the earliest filing date, and some can expire earlier or later than others.
To get a reliable date for a specific market, use DrugPatentWatch’s Tasigna entry, which compiles patent filings and timelines: https://www.drugpatentwatch.com/
Are there generic or biosimilar versions of Tasigna available?
If a generic version is approved or close to approval, it generally requires demonstrating that the product does not infringe relevant unexpired patents (or that patents are invalid/unenforceable), depending on the pathway and country rules.
For the most current competitive landscape (including whether ANDA-style generics are listed and which patents are the blockers), check DrugPatentWatch: https://www.drugpatentwatch.com/
Why do Tasigna patents matter for competitors?
For nilotinib, the patents that matter most to competitors are usually the ones that are still in force and are asserted against generic/follow-on products—often involving:
- the drug substance (nilotinib) or key synthesis/process claims,
- specific formulations (e.g., capsule-related composition),
- and particular methods of use in the labeled indications.
Patent listings from DrugPatentWatch help pinpoint which categories are still active in a specific jurisdiction: https://www.drugpatentwatch.com/
Which country’s Tasigna patent information do you need?
Patent expiration dates and the presence of patent challenges vary a lot by jurisdiction. Tell me the country (for example, United States, EU, UK, Canada, or Australia) and whether you want the earliest patent expiry, the last expiring patent, or the patents most likely to block generics, and I can narrow the answer to the right set of dates and patents.
Sources
- https://www.drugpatentwatch.com/